Achillion Pharmaceuticals (NASDAQ:ACHN)
The biotech market is eagerly awaiting phase 1 results from ACHN for their drug ACH-3422. This drug is structurally very similar to Gilead Sciences (NASDAQ:GILD) drug SOVALDI.
With the data imminent - we want to know what YOU think. (polls are open until ACHN halts for data)